• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Virta Health reports positive results from diabetes reversal study

June 6, 2022 By Sean Whooley

Virta HealthVirta Health announced today that its diabetes reversal treatment demonstrated improvements in those with type 2 diabetes.

San Francisco-based Virta Health launched in 2017 with the goal of reversing Type 2 diabetes using its technology platform to enable personalized remote care. Virta’s offerings include physician supervision, health coaches, an app and biomarker tracking tools, as well as a personalized nutrition plan for its patients in the hopes of reversing Type 2 diabetes.

Five-year data presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans showed lasting improvements in those with type 2 diabetes and prediabetes, including blood sugar control, clinically significant weight loss, reduced inflammation and improvements in other cardiometabolic health markers, according to a news release.

One-fifth of Virta patients completing five years of treatment experienced full remission (A1c <6.5% without any diabetes medications for at least 3 months). A third of patients achieved A1c below 6.5% without any diabetes medications or only requiring Metformin. Inflammatory markers, triglycerides, and HDL cholesterol all improved significantly, Virta said.

Nearly 50% of participants with type 2 diabetes were retained at five years. Among those who continued past year two, 72% remained for an additional three years through to year five.

Virta patients experienced persistent improvements in blood sugar on average, while prescriptions were reduced by nearly 50% across all diabetes drugs at five years. The average weight loss among participants was a decrease of 7.6%, exceeding the 5% benchmark for clinically significant weight loss by more than 50%, while the decrease in inflammatory markers signaled the success in reversing the progression of chronic kidney disease.

“Virta’s patients are helping redefine what long-term success can look like in type 2 diabetes care,” Virta advisor Dr. Alan Moses said in the release. “The patient outcomes set a new standard for real-world applications of diabetes treatment.”

At ADA, Virta also presented data from a two-year study through a partnership with the Department of Veterans Affairs (VA). The study demonstrated broad metabolic health improvements for Veteran patients, including long-term blood sugar reduction, clinically-significant weight loss, and medication deprescription.

Nearly two-thirds of veterans remained in treatment at two years, while patients who dropped out still saw notable improvements, including clinically-significant weight loss (5.6%) and a 50% reduction in prescribed diabetes medications.

Filed Under: Clinical Trials, Diabetes, Featured, Technology Tagged With: American Diabetes Association, Virta Health

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS